TB-500 Working in Preclinical Models TB-500 is thought to work primarily through the regulation of actin dynamics
However, on July 2324, 2026, the FDAs Pharmacy Compounding Advisory Committee (PCAC) voted on inclusion of three of KLOWs peptide compounds for the 503A Bulks List: BPC-157 : 86 voted in favor of inclusion, with one abstention TB-500 : 86 voted in favor of inclusion, with one abstention KPV : 86 voted in favor of inclusion, with one abstention Note: TB-500 is a fragment of the full-length thymosin beta-4 (43 amino acids)
By flagging it in Category 2, FDA signaled to pharmacies that BPC-157 is not permitted to be compounded under federal law (Section 503A) due to these safety uncertainties
A 5mg vial may contain as little as a few millimetres of visible powder
Read article A copper-binding tripeptide endogenous to human plasma, studied extensively in wound healing, collagen synthesis, antioxidant defense, and gene expression regulation within cellular research models
